Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRX-1074 in Early Course Schizophrenia
NCT02603458Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Primary completion
- Aug 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apimostinel in schizophrenia, sponsored by NYU Langone Health. Status: withdrawn.
02
Drugs
apimostinel
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02603458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603458.